2020 Virtual Pipeline Conference

The Epilepsy Foundation Pipeline Conference is going virtual!  

August 27-28, 2020

Registration Open Now.

Register by June 30, 2020, to take advantage of Early Bird Special Pricing. 

What is the Pipeline Conference?

The Pipeline Conference showcases the latest developments in the epilepsy pipeline from preclinical to right before FDA approval. This is a one-stop shop to get anyone up to speed on the landscape and latest news about epilepsy.

Registering for this event gives you:

  • Access to over 50 different presentations on products and trends in epilepsy development (See Agenda
  • Opportunity to interact with drug and device developers in the epilepsy space throughout the event
  • A week pass following the event to re-watch any of the sessions you might have missed 
  • Epilepsy Foundation Shark Tank voting to select the latest innovative idea for the Foundation to seed fund

New Opportunity

Want to present at Pipeline?

Although all general session slots have been filled, we are accepting abstract submissions for poster and platform sessions. Select "Abstract Submission" when registering and get the link to submit your information! DEADLINE EXTENDED to July 13, 2020.

Agenda

Times are eastern time (ET). 

Day 1 – Thursday, August 27, 2020

Welcome and Introduction – 9:00-9:10 A.M.

  • Jacqueline French, MD, Chief Medical and Innovation Officer, Epilepsy Foundation  
  • Laura Thrall, President & CEO, Epilepsy Foundation

Session I: Diagnosis And Detection Devices – 9:10-10:50 A.M.

  • Lectures
    • Can SUDEP be avoided with devices?– Sam Lhatoo MD, FRCP, UT Health 
    • My Seizure Gauge, Seizure Forecasting, and the Future of Therapeutics –  Dean Freestone PhD, Co-Founder, Seer Medical 
  • Diagnosis and Detection Device Presentations 
    • SeizeIT, Byteflies & UCB – Benjamin Vandendriessche, CMO & Gergely Vertes, Seizure Freedom Mission Solution Accelerator 
    • Embrace Platform and Device, Empatica – Matteo Lai, Co-Founder & CEO
    • Epihunter Tracker, Epihunter – Dirk Loeckx PhD, Chief Scientific Officer
    • Nelli Seizure Monitoring Tool – Glen Fotland, Founder, Go North Medical, Neuro Event Labs
    • TMS-EEG, Kings College London – Isabella Premoli MD 
    • UNEEG 24/7 SubQ, UNEEG Medical – Lykke Blaabjerg, Head of Clinical Affairs 
    • Epi-Minder sub-scalp system, Epi-Minder – Mark Cook, Director of Neurology, Melbourne University
    • Epilog wearable device, Epitel – Mark Lehmkuhle PhD, CEO/CTO

Break – 10:50-11:00 A.M.

Session II: Therapeutic Devices – 11:00-11:35 A.M. 

  • Therapeutic Device Presentations
    • Cathodal Transcranial Direct Current Stimulation, tDCS, Neuroelectrics  –  Alexander Rotenberg MD 
    • DyNeuMo implantable device and platform, University of Oxford – Timothy Denison  
  • Session I & II Discussion 

Session III: COVID impact on recruitment to clinical trials – 11:35 A.M.-12:05 P.M. 

Break – 12:05 P.M.-12:35 P.M.

Session IV: What We Still Need In Drugs For Focal Epilepsy – 12:35-2:20 P.M.

  • Lectures
    • ​What would make a new focal epilepsy drug successful in the marketplace? – Daniel Friedman MD, New York University Langone Medical Center
    • Efficient Trials and Ultra-Rare Diseases – An Overview of the 2019 Research Roundtable for Epilepsy – Dennis Dlugos MD, Children’s Hospital of Philadelphia
  • Drug Presentations
    • 2-Deoxy-d-Glucose (2DG), University of Wisconsin  – Thomas Sutula MD, PhD 
    • Inhibitory interneuron cell therapy, Neurona Therapeutics – Cory Nicholas PhD, CEO & Co-Founder 
    • Revivo-5061, Revivo Therapeutics – Doug Cowart PharmD, CEO 
    • Cenobamate and Carisbamate, SK Life Sciences – William Rosenfeld MD
    • Kv7 potassium channel modulators for the treatment of epilepsy, Xenon Pharma – Ernesto Aycardi MD, Chief Medical Officer  
    • CVL-865, Cerevel Therapeutics – Rachel Gurrell 
    • mGlu2 PAM JNJ-40411813 and Levetiracetam:  A potential rational polypharmacy treatment?Janssen Research & Development, a division of Janssen Pharmaceutica N.V.  – Marc Ceusters, PhD
  • Session III & IV Discussion

Break – 2:20-2:30 P.M   

Update From 2019 Shark Tank Winners – 2:30-2:50 P.M.

  • Update from 2019 winner #1 – Rachel Kuperman, Eysz 
  • Update from 2019 winner #2 – Jody McNannay, Curadite

2020 Shark Tank Competition – 2:50-4:50 P.M.

  • Moderator: Jacqueline French, MD, Chief Medical Innovation Officer, Epilepsy Foundation

    • NAO-VNS: A disruptive implantable neurostimulator for the treatment of epilepsy – Synergia Medical 
    • Minimally invasive implantable graphene electrodes – Brain Scientific Inc.  
    • Automated privacy enhancement for seizure videos – Mocxa  
    • A night-time SUDEP prevention device – Soterya 
    • Epilepsy emergency band – Keely McCarthy, mother of a child with epilepsy   
  • Discussion, voting, and awarding  

Award to Mary Ann Brodie: Accelerator Award Virtual Reception & Presentation – 4:50 P.M. 

Day 2 – Friday, August 28, 2020 

Day 2 Welcome – 9:00-9:05 A.M. 

  • Kathleen Farrell, MB BCh BAO, Senior Director of Clinical Research, Epilepsy Foundation

Session V: Screening – 9:05-9:35 A.M.

  • Lectures 
    • Status report on NINDS Translational Epilepsy Research – Brian Klein PhD, NINDS 
    • Screening Across the Board: Where are we and where should we be going? – Mike Rogawski MD, PhD, University California Davis 
  • Screening
    • NeuCyte Platform, NeuCyte – Thomas Portmann PhD, Associate Director, Head of Research

 Session VI: Genetics – 9:35-10:20 A.M.

  • Lecture
    • Mechanisms of intervention in single gene diseases – Ingrid Scheffer, MD, University of Melbourne
  • Gene Modifying Therapies 
    • STK-001, Stoke Therapeutics – Barry Ticho MD, PhD, Chief Medical Officer 
    • EXT101, Encoded Therapeutics – Rosie O’Donnell MD, Senior Advisor, Clinical Development
  • Session V & VI Discussion on screening and genetics

Session VII: Data-Driven Solutions – 10:20-11:00 A.M.

  • Lectures 
    • What can we learn from aggregated data and why should we be capturing it? – David Voccola, Prometheus Research, Co-Founder 
    • Epilepsy Digital Experience Navigator (EDEN) – Jacqueline French MD, Chief Medical Innovation Officer, Epilepsy Foundation
    • Epilepsy Learning Healthcare System – Brandy Fureman PhD, Chief Outcomes Officer and VP Research & New Therapies, Epilepsy Foundation
  • Session VII Discussion  

Break – 11:00-11:10 A.M.

Session VIII: Rare And Ultra-Rare Diseases (Part 1) – 11:10 A.M.-12:20 P.M. 

  • Rare and Ultra-Rare Disease Drug Therapies (Part 1)
    • KB-3061, Knopp Biosciences – Steven Dworetzky PhD, VP Discovery Research 
    • Tak-935/OV935, Takeda Pharmaceuticals – Mahnaz Asgharnejad PharmD, VP Clinical Development 
    • UX-068, Ultragenyx  – Melanie Brandabur MD, Medical Director 
    • VAL-0417 and VAL-1221, Valerion Therapeutics – Matthew Gentry PhD 
    • Epidiolex for Tuberous Sclerosis – Farhad Sahebkar MD, Senior Medical Director, Greenwich Biosciences 
    • ZX008, Zogenix – Glenn Morrison PhD, VP Global Clinical Development 
    • Anavex 2-73, Anavex Life Sciences – Walter Kaufmann MD, Chief Medical Officer 

Lunch – 12:20 P.M.-12:50 P.M.

Session VIII: Rare And Ultra-Rare Diseases – 12:50-1:40 P.M. (Part 2) 

  • AE116, Aeovian Pharmaceuticals  – Stelios Tzannis PhD, President & CEO
  • PRAX-330, Praxis Precision Medicines – Bernard Ravina MD, MS, Chief Medical Officer 
  • NBI-921352, Neurocrine Biosciences – Dietrich Haubenberger MHSc, MD, Medical Director, Early Clinical Development 
  • Session IX Discussion 

Session IX: Reformulated Drugs And Other Therapies – 1:40-2:55 P.M.

  • Buccal diazepam, Aquestive Therapeutics – Michael Rogawski MD, PhD, Consultant 
  • Staccato alprazolam, Engage Therapeutics – Jouko Isojarvi MD, PhD, Chief Medical Officer 
  • Novel intramuscular diazepam, Xeris Pharmaceuticals – Anh Nguyen MD, Director, Strategy Operations 
  • CT-010, Cerebral Therapeutics – Dan Abrams MD, CEO 
  • The gut brain axis and epilepsy, Bloom Science – Christopher Reyes PhD, Co-Founder & CEO
  • Ganaxolone IV, Marinus Pharmaceuticals – Alex Aimetti PhD, VP Scientific Affairs 
  • Session X Discussion

Breakout Rooms for Platforms and Poster Sessions 2:55-3:55 P.M.

Closing Remarks – 4:00 P.M.

  • Jacqueline French MD, Chief Medical and Innovation Officer, Epilepsy Foundation 

Innovation and Action to END EPILEPSY

Are you someone impacted by epilepsy? Following the Pipeline Conference, join us for Innovation and Action to END EPILEPSY on August 29, a nationwide virtual community day organized by and for people affected by epilepsy.  

Thank You to Our Sponsors

Thank you for your support to make the 2020 Epilepsy Foundation Pipeline Conference a successful event and your commitment to the epilepsy community.

2020 Pipeline Conference Sponsors

Watch Footage from the 2018 Pipeline Conference

Authored By: 
Epilepsy Foundation Research
Authored Date: 
05/2020